In vitro susceptibility testing of aztreonam-avibactam against predominantly NDM-producing Enterobacterales in Peru
Microbiology Spectrum · 2026
DOI: 10.1128/spectrum.00762-26 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbiology Spectrum, 2026. Verfasst von Coralith Garcia und 24 weiteren Autor:innen. Beteiligte Einrichtung: Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Peru. Hauptthemen laut MEDLINE: Aztreonam, beta-Lactamases, Anti-Bacterial Agents, Azabicyclo Compounds. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer Global Medical Grants.
Abstract (Originalsprache)
Metallo-β-lactamase-producing Enterobacterales are distributed worldwide, but some Latin American countries show a higher prevalence. Aztreonam-avibactam (ATM-AVI) may be an option for treating these infections. To evaluate in vitro susceptibility to aztreonam (ATM) alone and ATM-AVI in carbapenem-non-susceptible Enterobacterales isolates, based on the type of carbapenemase production, we prospectively collected carbapenem-non-susceptible Enterobacterales isolates from Peruvian hospitals during 2023–2024. Identification and susceptibility testing were performed by commercial panels and disk diffusion. Carbapenemases were detected by immunochromatography. ATM and ATM-AVI MICs were determined using broth microdilution panels with avibactam fixed at 4 µg/mL. The non-susceptible isolates to ATM-AVI and those with double production of carbapenemases underwent whole-genome sequencing. A total of 438 Enterobacterales isolates were analyzed; carbapenemase production was detected in 422 (96.3%) and NDM was the most frequent (61.9%). Coproduction of NDM + KPC in K. pneumoniae and NDM + OXA-48-like in Escherichia coli was observed. Overall, 99.3% were susceptible to ATM-AVI; MIC 50 and MIC 90 were 0.12 and 2 µg/mL, respectively. Overall, K. pneumoniae isolates had lower MIC 50 and MIC 90 values to ATM-AVI (0.12 and 0.5 µg/mL) compared to E. coli (0.5 and 4 µg/mL). Three E. coli isolates were resistant to ATM-AVI (MIC ≥ 8 µg/mL), they belonged to ST410, ST167, and ST10 and harbored a YRIN insertion in PBP3 along with CYM-type, PER-type, and CTX-M-type beta-lactamase genes. ATM-AVI demonstrated potent activity against carbapenem-non-susceptible Enterobacterales , including those producing NDM, which is the carbapenemase most frequently detected in Peruvian hospitals. IMPORTANCE Enterobacterales isolates cause common illnesses in humans. Carbapenems are the antibiotics used to treat several of these infections, and increasingly, isolates resistant to these antibiotics are found. The most important mechanism of resistance to carbapenem among Enterobacterales is the production of enzymes called carbapenemases. Our results allowed us to recognize that NDM is the most frequent type of carbapenemase detected. Most of the antimicrobials available do not cover the E nterobacterales carrying NDM carbapenemase. In this scenario, we found that the new combination of drugs, aztreonam-avibactam, has high in vitro efficacy against most of the carbapenem-resistant isolates and against those isolates carrying NDM carbapenemase.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Peru.
- Hospital Nacional Cayetano Heredia, Lima, Peru.
- Hospital Nacional Guillermo Almenara Irigoyen EsSalud, Lima, Peru.
- Hospital Nacional Dos de Mayo, Lima, Peru.
- Instituto de Investigaciones en Ciencias Biomédicas, Universidad Ricardo Palma, Lima, Peru.
- Hospital Nacional Daniel Alcides Carrión, Callao, Peru.
ORCID-Profile: Coralith Garcia, Diego Cuicapuza, Pablo Tsukayama, Fiorella Krapp
Förderung
- Pfizer Global Medical Grants
Zitieren
APA
Garcia, C., Reyes, Y., Astocondor, L., Caytuiro, L., Riveros, M., Amaro, C., Andrade, S., Hernández, L., Sandoval, R., Peréz-Lazo, G., Cucho, C., Melo, M., Sabogal, I., Lino, L., Cuaresma, E., Olivares, A., Lachira, A., Michilot, K., Ramos, J., …, & Krapp, F. (2026). In vitro susceptibility testing of aztreonam-avibactam against predominantly NDM-producing Enterobacterales in Peru. Microbiology Spectrum. https://doi.org/10.1128/spectrum.00762-26
Vancouver
Garcia C, Reyes Y, Astocondor L, Caytuiro L, Riveros M, Amaro C, et al. In vitro susceptibility testing of aztreonam-avibactam against predominantly NDM-producing Enterobacterales in Peru. Microbiology Spectrum. 2026. doi:10.1128/spectrum.00762-26
BibTeX
@article{Garcia2026,
author = {Garcia, Coralith and Reyes, Yelinda and Astocondor, Lizeth and Caytuiro, Liliana and Riveros, Maribel and Amaro, Catherine and Andrade, Stephanie and Hernández, Luis and Sandoval, Roxana and Peréz-Lazo, Giancarlo and Cucho, Carolina and Melo, Manuel and Sabogal, Ivan and Lino, Liz and Cuaresma, Edwin and Olivares, Araceli and Lachira, Arnaldo and Michilot, Kattya and Ramos, Juan and Diaz, Roberto and Briones, Alexander and Burgos, Segundo and Cuicapuza, Diego and Tsukayama, Pablo and Krapp, Fiorella},
title = {In vitro susceptibility testing of aztreonam-avibactam against predominantly NDM-producing Enterobacterales in Peru},
journal = {Microbiology Spectrum},
year = {2026},
doi = {10.1128/spectrum.00762-26}
}
EUVIMED